Penumbra Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
88,848.00
125,510.00
186,095.00
263,317.00
333,764.00
444,938
Cost of Goods Sold (COGS) incl. D&A
30,972.00
42,668.00
62,037.00
91,312.00
116,551.00
153,237
Gross Income
57,876.00
82,842.00
124,058.00
172,005.00
217,213.00
291,701
SG&A Expense
59,002.00
79,833.00
119,879.00
172,179.00
215,477.00
260,768
EBIT
1,126.00
3,009.00
4,179.00
1,350.00
1,265.00
30,933
Unusual Expense
-
-
-
-
100.00
31,785
Non Operating Income/Expense
474.00
309.00
696.00
1,842.00
1,342.00
504
Pretax Income
1,255.00
3,139.00
4,024.00
869.00
2,476.00
1,608
Income Tax
5,354.00
894.00
1,659.00
15,683.00
3,611.00
4,403
Equity in Affiliates
-
-
-
-
1,430.00
3,101
Consolidated Net Income
887.00
5,511.00
2,365.00
14,814.00
4,657.00
2,910
Net Income
887.00
5,511.00
2,365.00
14,814.00
4,657.00
6,601
Net Income After Extraordinaries
887.00
5,511.00
2,365.00
14,814.00
4,657.00
6,601
Net Income Available to Common
887.00
833.00
1,084.00
14,814.00
4,657.00
6,601
EPS (Basic)
0.04
0.03
0.08
0.44
0.13
0.18
Basic Shares Outstanding
24,431.50
24,431.50
11,993.40
30,464.60
32,978.10
34,138.20
EPS (Diluted)
0.04
0.03
0.08
0.44
0.13
0.18
Diluted Shares Outstanding
24,431.50
24,431.50
14,219.70
33,478.10
35,319.10
36,086.80
EBITDA
449.00
3,760.00
5,931.00
947.00
5,046.00
37,101
Other Operating Expense
-
-
-
1,176.00
471.00
-
Non-Operating Interest Income
345.00
439.00
541.00
2,323.00
2,653.00
2,964
Other After Tax Income (Expense)
3,212.00
3,266.00
-
-
-
-
Preferred Dividends
-
6,344.00
1,281.00
-
-
-

About Penumbra

View Profile
Address
One Penumbra Place
Alameda California 94502
United States
Employees -
Website http://www.penumbrainc.com
Updated 07/08/2019
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It focuses on developing products for use by the specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists, and vascular surgeons. Its products are designed to address ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.